Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$3.08 - $7.79 $126,896 - $320,948
-41,200 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$2.02 - $3.08 $4,242 - $6,468
-2,100 Reduced 4.85%
41,200 $84,000
Q2 2020

Aug 14, 2020

SELL
$2.1 - $3.42 $123,242 - $200,709
-58,687 Reduced 57.54%
43,300 $127,000
Q1 2020

May 15, 2020

SELL
$2.31 - $4.43 $40,887 - $78,411
-17,700 Reduced 14.79%
101,987 $244,000
Q4 2019

Feb 14, 2020

BUY
$2.82 - $12.9 $165,779 - $758,352
58,787 Added 96.53%
119,687 $533,000
Q3 2019

Nov 14, 2019

SELL
$4.33 - $11.64 $226,892 - $609,936
-52,400 Reduced 46.25%
60,900 $630,000
Q2 2019

Aug 14, 2019

BUY
$4.6 - $10.13 $521,179 - $1.15 Million
113,300 New
113,300 $651,000

Others Institutions Holding SLDB

About Solid Biosciences Inc.


  • Ticker SLDB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 7,533,080
  • Market Cap $36.5M
  • Description
  • Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...
More about SLDB
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.